Drugs / JNJ-63898081
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03926013 | May 2019 → Aug 2021 | neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-63898081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03926013 ↗ |